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ABSTRACT
Release of RNA polymerase II (Pol II) from promoter-
proximal pausing has emerged as a critical step reg-
ulating gene expression in multicellular organisms.
The transition of Pol II into productive elongation re-
quires the kinase activity of positive transcription
elongation factor b (P-TEFb), which is itself under
a stringent control by the inhibitory 7SK small nu-
clear ribonucleoprotein (7SK snRNP) complex. Here,
we provide an overview on stimulating Pol II pause
release by P-TEFb and on sequestering P-TEFb into
7SK snRNP. Furthermore, we highlight mechanisms
that govern anchoring of 7SK snRNP to chromatin as
well as means that release P-TEFb from the inhibitory
complex, and propose a unifying model of P-TEFb
activation on chromatin. Collectively, these studies
shine a spotlight on the central role of RNA binding
proteins (RBPs) in directing the inhibition and acti-
vation of P-TEFb, providing a compelling paradigm
for controlling Pol II transcription with a non-coding
RNA.
INTRODUCTION
‘If you’re going to try, go all the way. Otherwise, don’t even
start.’ With these words, a late American poet Charles
Bukowski has unwittingly commented on an important reg-
ulatory step in gene transcription by Pol II in multicellular
organisms. Namely, to respond to intra- and extra-cellular
signals, cells possess a highly sophisticated transcription ap-
paratus, wherein Pol II is the principle player. With the help
of an extensive entourage of general and gene-specific tran-
scription factors, Pol II goes through a series of specific
steps while transcribing protein-coding and non-protein
coding genes. These steps include loading of Pol II to gene
promoter, initiation of RNA synthesis from transcription
start site (TSS), promoter-proximal pausing (herein referred
to as pausing), elongation along the length of a gene, termi-
nation soon after transcription end site (TES) and eventual
re-initiation.
Up to the turn of the new millennium, a predominantly
held view based mainly on yeast models of gene transcrip-
tion claimed that Pol II loading to promoters was the main
rate-limiting step in the Pol II transcription cycle. How-
ever, pioneering work in late 1980’s and early 90’s on hu-
manMYC and FOS (1,2), fruit flyHSP70 (3), as well as the
human immunodeficiency virus type 1 (HIV-1) transcrip-
tion (4) began to challenge this prevailing paradigm. These
studies showed that Pol II could start with transcription but
fail to generate full-length transcripts in the absence of ad-
ditional stimuli due to a block in early elongation. Finally,
with the help of various genome-wide approaches which
track Pol II along DNA as well as nascent transcripts, in-
vestigators have revealed that once it engages transcription,
the bulk of Pol II is found at promoter-proximal pause sites,
30–60 nucleotides downstream of TSS (5,6). Thus, the great
deal of regulation of gene expression, particularly at devel-
opmental genes and those involved in stimulus-controlled
pathways (7), takes place at the level of Pol II pausing and
Pol II release into early transcription elongation. In this
survey, we first review the fundamentals of gene transcrip-
tion control by P-TEFb and its sequestration within the in-
hibitory 7SK snRNP complex. We next focus on recent de-
velopments in the field which are beginning to reveal mech-
anisms that anchor 7SK snRNP to chromatin and liberate
P-TEFb from this inhibition, illustrating a highly controlled
step in the transition from paused to elongating Pol II.
Stimulating Pol II pause release with P-TEFb
The critical factor that triggers the release of paused Pol
II into productive elongation at almost all metazoan genes
is P-TEFb (8,9). It is an evolutionarily conserved het-
erodimeric cyclin-dependent kinase (Cdk9/CycT), which is
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Figure 1. P-TEFb kinase stimulates the transition of Pol II from promoter-
proximal pausing into productive elongation. Top: recruitment of Pol II
by general transcription factors (GTFs) through TATA-binding protein
of the core promoter recognition complex TFIID results in the formation
of a PIC. The CTD of Pol II is represented as a tail, wherein white circles
depict unphosphorylated Serine residues at position 2, 5 and 7 within the
consensus heptapeptide repeat. Black arrow depicts transcription start site
(TSS). While rapid Pol II initiation ensues (depicted in light blue), Pol II
pauses (depicted in blue) at promoter-proximal pause sites due to the ac-
tions of NELF and DSIF which are both in non-phosphorylated forms
(white circles). At this stage, the CTD has been phosphorylated already by
Cdk7 of TFIIH at Ser5 and Ser7 (yellow circles). A short RNA transcript is
depicted in red. Bottom: catalytically active P-TEFbwithin SEC stimulates
the release of paused Pol II into elongation (dashed red arrow) by phos-
phorylating the CTDat Ser2, NELF andDSIF (green circles).While phos-
phorylated NELF dissociates from Pol II, phosphorylated DSIF becomes
a positive elongation factor and recruits Tat-SF1 and PAF1C to elongat-
ing Pol II. In turn, PAF1C can promote the recruitment of Cdk12/CycK,
which in concert with P-TEFb catalyzes P-Ser2 during Pol II elongation,
yielding an increasingly longer RNA transcript (red).
in humans composed of the catalytic Cdk9 and a regula-
tory CycT1, T2a or T2b subunits. After its initial identifi-
cation from Drosophila nuclear extracts (10), P-TEFb rose
to prominence because it was discovered to be an essen-
tial cellular co-factor for stimulating HIV-1 gene expres-
sion by the viral transactivator of transcription (Tat) (11–
13). Without Tat, Pol II gets loaded to and initiates tran-
scription from the viral promoter but pauses soon after-
ward due to the actions of multi-subunit negative transcrip-
tion elongation factors (N-TEFs) NELF andDSIF (14,15).
Thus only short viral transcripts are produced, measuring
in length barely enough to contain transactivation response
(TAR) element (16), a stable stem-loop structure that con-
stitutes another key component for HIV-1 transcription. To
overcome the early transcriptional blockade, Tat employs
its activation domain (AD) to recruit P-TEFb to Pol II
via TAR (12), whereby Cdk9 meets its three principal sub-
strate targets: Y1S2P3T4S5P6S7 heptapeptide repeats of the
C-terminal domain (CTD) of Pol II’s biggest subunit Rbp1,
as well as NELF-E and Spt5 subunits of NELF and DSIF,
respectively.
Although P-TEFb may target additional components in-
fluencing Pol II pausing (17), phosphorylation events ex-
emplified at HIV-1 define Pol II transition from pausing
into productive elongation atmost genes inmulticellular or-
ganisms (Figure 1). While P-TEFb catalyzes the CTD Ser-
ine 2 phosphorylation (P-Ser2) to tether additional elonga-
tion, RNAmaturation and chromatin modifying factors to
Pol II (18–20), NELF-E phosphorylation leads to NELF
dissociation from it (21). Furthermore, Spt5 phosphoryla-
tion transforms DSIF into a positive elongation factor, at-
tracting Tat-SF1 and PAF1 complex (PAF1C) to elongat-
ing Pol II (22,23). Subsequently, PAF1C can in turn re-
cruit the Cdk12/CycK complex (24), which could in con-
cert with P-TEFb contribute to the progressive levels of Pol
II P-Ser2 along gene’s body and proper Pol II termination
(17,25,26). In contrast to the wealth of in vivo data showing
that P-TEFb catalyzes the P-Ser2 mark (20,26–33), purified
P-TEFb exhibited a robust P-Ser5 activity in vitro (34,35),
possibly reflecting the lack of cellular complexity in the in
vitro systems.
The demonstration that HIV-1 Tat stimulated Pol II elon-
gation through P-TEFb ushered in an era of efforts aim-
ing to reveal P-TEFb tethering mechanisms to endogenous
genes. As has the number of genes requiring P-TEFb for
paused Pol II release grown to encompass almost an en-
tire gene collection (32,36), so has the variety of factors
promoting recruitment of P-TEFb to genes. Among oth-
ers, these include classical transcription factors and co-
activators such as NF-kB, CIITA, p53 and c-Myc (32,37–
39), the BET family acetyl-lysine recognizing chromatin
adaptor protein Brd4 (40–42), and the nuclear cap-binding
protein complex which links pre-mRNA capping to tran-
script elongation (30,43).
Importantly, P-TEFb has been subsequently identified
as an integral component of many super elongation com-
plexes (SECs), which can be formed by different combina-
tions of the ELL familymembers (ELL1, ELL2, ELL3), the
AF4/FMR2 SEC-scaffolding family members AFF1 and
AFF4, as well as ENL andAF9 proteins (9,44–47). Of note,
ELL1, AFF1, AFF4, ENL and AF9 have been described
previously as fusion partners of the DNA-binding domain
of the mixed lineage leukemia (MLL) gene as a result of
in-frame gene translocations (48). In turn, the potent Pol
II elongation stimulatory activity of SECs is mis-targeted
to MLL-dependent genes, causing childhood hematologi-
cal malignancies. In addition, Tat can deliver an entire SEC
containing AFF1 as a scaffolding component via TAR for
productiveHIV-1 transcription (49). Under normal circum-
stances, recruitment of P-TEFb as a part of many SECs can
be accomplished by the Pol II CTD interacting Mediator
and Integrator complexes (50,51), the BET family protein
member Brd4 (52) and PAF1C (53).
KEEPING P-TEFb IN CHECK BY 7SK snRNP
Befitting the vital role of P-TEFb in Pol II transcription, its
kinase activity is kept under a tight control inmetazoan cells
(5,9). The first glimpse into the negative regulation came by
groundbreaking studies showing that an abundant, Pol III-
transcribed non-coding 7SK small nuclear RNA (7SK) of
330–332 nucleotides in length (54,55) and of hitherto mys-
terious function binds to P-TEFb and inhibits its kinase ac-
tivity (56,57). Moreover, this work documented that chem-
ical inhibition of Pol II transcription by 5,6-dichloro-1--
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Figure 2. Biogenesis of core and canonical 7SK snRNP. Following the transcription of RN7SK by Pol III, nascent 7SK folds into a structure that may
consist of four stem loops (SL1-4) as displayed on the left. LA andMePCE prevent 7SK nucleolytic degradation by binding its 3′-terminal U-rich sequence
and by binding the basal part of the 7SK SL1 and capping the 5′ end of 7SK, respectively (Step 1). The capping (depicted as black circle) might provoke the
replacement of LA in the transient 7SK snRNP by LARP7, which in addition to the 3′-terminal U-rich sequence binds 7SK SL4, ensuring 7SK stability.
Moreover, LARP7 binds MePCE, provoking tighter LARP7-7SK interaction and inhibition of the MePCE capping activity, yielding a stable core 7SK
snRNP (Step 2). Finally, HEXIM1/2 dimers bind the proximal and distal parts of 7SK SL1 through their ARMs, leading to the exposure of the dimeric
coiled-coil binding surface for active P-TEFb (Cdk9 is in green) phosphorylated at Threonine 186 (depicted as green circle on Cdk9). Inhibition of P-TEFb
(Cdk9 is in red) by HEXIM1/2 ensues, concluding formation of the canonical 7SK snRNP (Step 3).
D-ribofuranosylbenzimidazole (DRB) and actinomycin D
(ActD) or ultraviolet (UV) irradiation activates P-TEFb
by dissociating it from 7SK in a reversible manner, under-
scoring that regulated de-repression of P-TEFb could be
an important way to fine-tune Pol II pause release in re-
sponse to diverse sets of circumstances. Of note, the por-
tion of P-TEFb bound to 7SK varies between different cell
types: while this fraction is about half in growingHeLa cells
(56,57), it reaches close to 90% in Jurkat T cells or human
primary blood lymphocytes (58,59).
Subsequently, it has become apparent that 7SK does not
impact P-TEFb by itself but rather serves as a scaffold for
proteins which enable its own stability and inhibition of P-
TEFb (Figure 2 and Table 1). In addition to 7SK and P-
TEFb, the canonical 7SK snRNP complex is composed of
three RBPs: P-TEFb inhibitor HEXIM1 (and/or its para-
log HEXIM2), LA-related protein family member LARP7
and the 7SK  -methylphosphate capping enzyme MePCE
(5,9,60–63). Finally, recent evidence suggests that AFF1
and AFF4 accompany P-TEFb in 7SK snRNP as well (49).
Structure of the inhibitory complex has not been solved,
and conclusions from previous studies differ in what the
exact structure of 7SK within the snRNP might be (64–
66). Nevertheless, 7SK was proposed to form complex and
dynamic secondary structures that may consist of either
eight highly conserved structuralmotifs (M1-8) or four stem
loops (SL1-4), creating binding surfaces for RBPs. Of note,
outside of the canonical 7SK snRNP, 7SK can be also as-
sembled within alternative snRNPs (Table 1; for details, see
text below).
Biogenesis of the canonical 7SK snRNP particle is pre-
ceded by the assembly of core 7SK snRNP, consisting of
7SK, LARP7 and MePCE (27,67) (Figure 2). Namely, all
7SK molecules within the core are bound stably to LARP7
and MePCE as depletion of either one of them via RNAi
triggers 7SK degradation in cells (60,61,68). Moreover, cell
stress-inducing agents that release P-TEFb andHEXIM1/2
from 7SK snRNP leave core 7SK snRNP intact, allowing
for prompt re-association of these factors once cell stress
subsides (27,67). Current evidence suggest that upon 7SK
synthesis, LA protein stabilizes it by binding its 3′-terminal
U-rich sequence (69,70), while MePCE binds to the basal
part of the 7SK SL1 and caps 7SK at its 5′ end to en-
able its stability (71). Perhaps due to the capping (72), LA
leaves this transient 7SK snRNP complex and is replaced
by LARP7, which employs its La and RRM1 motifs to
bind the 7SK 3′-terminal U-rich sequence and the pre-
ceding SL4, protecting 7SK from nucleolytic degradation
(27,60,71,73). Upon this binding event, affinity between
LARP7 and MePCE increases, which in return provokes
the tighter LARP7-7SK interaction and inhibits the cap-
ping activity of MePCE (27,67). This inhibition effectively
prevents 7SK de-capping reaction and concludes formation
of core 7SK snRNP.
Upon the assembly, core 7SK snRNP sets the stage for
incorporation and subsequent inhibition of P-TEFb. Crit-
ical factors for both steps turn out to be HEXIM pro-
teins, which are sequestered into the snRNP as homo- or
hetero-dimers upon binding 7SK (62,63,74–76). Specifi-
cally, HEXIM1 dimers bind cooperatively to a proximal
and distal part of 7SK SL1 through arginine-rich RNA-
binding motif (ARM) which is positioned within centrally
locatedHEXIM1’s positively charged region (62,77–79). As
a result, HEXIM1 auto-inhibitory conformation mediated
by the N-terminal domain and negatively charged region is
relieved (62,75,77), exposing the C-terminal dimeric coiled-
coil region that provides the binding surface for the CycT1
subunit of P-TEFb (74,80,81). Inhibition of P-TEFb by
HEXIM1 ensues, most likely via blocking ATP binding to
Cdk9 (75). In addition, through its C-terminal RRM3 mo-
tif, LARP7 interacts with Cdk9 to further stabilize P-TEFb
incorporation (27,71,82). Finally, Cdk9 T loop phosphory-
lation at Threonine 186 (P-Thr186) is required for the as-
sembly of P-TEFb into 7SK snRNP (75,83). Because this
phosphorylation is the hallmark of activation of any cyclin-
dependent kinase, P-TEFb within 7SK snRNP is in a pre-
activated form, fully ready to promote Pol II pause release
upon its liberation from the inhibitory complex.
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Table 1. 7SK forms canonical and alternative snRNPs in cells
Canonical 7SK snRNP Factor Mode of action
Core 7SK snRNP 7SK RNA scaffold of the complex.
LARP7 Binds 3′ end and SL4 of 7SK to enable 7SK stability and binds P-TEFb to
promote its incorporation into 7SK snRNP.
MePCE Binds the basal part in SL1 of 7SK and caps 7SK at 5′ end to enable 7SK
and LARP7 stability.
P-TEFb inhibitors HEXIM1/2 Binds proximal and distal parts in SL1 of 7SK to bind and inhibit
P-TEFb.
P-TEFb Cdk9 Catalytic subunit of P-TEFb that is inhibited by HEXIM1/2.
CycT1/T2a/T2b Regulatory subunit of P-TEFb that provides binding surface for
HEXIM1/2.
P-TEFb auxiliary factor AFF1, AFF4 Binds P-TEFb and serves as a scaffold for SEC assembly.
7SK-hnRNP snRNP Factor Mode of action
Core 7SK snRNP 7SK, LARP7, MePCE Platform for hnRNPs and RNA helicase A upon inhibition of Pol II
transcription.
hnRNPs and RNA helicase A hnRNP A1, A2/B1, Q, R
and RNA helicase A
Bind SL3 of 7SK to enable the release of P-TEFb and HEXIM1 from the
canonical 7SK snRNP.
7SK–BAF snRNP Factor Mode of action
7SK 7SK Scaffolds BAF complex with Pol II and promotes occupancy and function
of BAF at enhancers.
BAF subunits of BAF complex Inhibits Pol II transcription at enhancers.
Table summarizes three known 7SK-containing snRNPs, along with their composition and mode of action for each factor.
ANCHORING 7SK snRNP TO CHROMATIN
That 7SK snRNP represents the major cellular reservoir of
transcriptionally inactive but poised P-TEFb has raised an
important question of how does the inhibitory complex en-
gage with transcriptionalmachinery to enable the transition
into productive Pol II elongation. A previous work reported
that in contrast to all other abundant snRNPs, 7SK snRNP
is not tightly associated with any nuclear compartment in-
cluding chromatin (84). The study gave rise to a view that
simple diffusion of this abundant snRNPmay provide a ba-
sis for delivering P-TEFb, once released from 7SK snRNP,
to any genomic location in a timely manner. However, a
mass-spectrometry analysis of factors bound to transcrip-
tionally engaged Pol II detected the presence of Cdk9 aswell
as HEXIM1 and 7SK (85). In a separate report, P-TEFb
was found to assemble into pre-initiation complex (PIC)
with non-phosphorylated Pol II and many other factors in-
cluding the 7SK snRNP components HEXIM1, LARP7
and 7SK (86). Correspondingly, P-TEFb isolated from the
PIC failed to phosphorylate the CTD of Pol II in vitro. To-
gether, these studies illustrate that a fraction of P-TEFb
held within the inhibitory 7SK snRNP interacts with Pol
II, suggesting that the inactive pool of P-TEFb could be em-
bedded with Pol II on chromatin.
The first example of 7SK snRNP anchoring to chro-
matin came from studying the usual suspect, HIV-1 (86,87).
This work revealed HEXIM1 and LARP7 co-occupying
the viral core promoter with P-TEFb, and this same sce-
nario was soon to be recapitulated at promoters of stimulus-
dependent primary response genes (PRGs) (88), provid-
ing evidence that 7SK snRNP tethered to chromatin could
serve as a source of P-TEFb stimulating Pol II escape from
pausing. Importantly, a recent study has put this initial
discoveries into a genome-wide context (89,90). Through
chromatin isolation by RNA purification and subsequent
sequencing (ChIRP-seq), the authors observed extensive
7SK occupancy along the entire transcribed loci of about
3500 active protein-coding genes in murine embryonic stem
(mES) cells and human cells, with prominent and minor
peaks encompassing TSSs and TESs, respectively, largely
mirroring Pol II occupancy. In addition, higher levels of
7SK were detected at active enhancers and in particular
at densely clustered enhancer elements also known as su-
per enhancers (SEs), collectively invoking a role for 7SK
in controlling Pol II transcription across genome. Of note,
compared to promoters, the 7SK at SEs was not associated
with proportional levels of N-TEFs and the canonical 7SK
snRNP component HEXIM1, implicating 7SK in impact-
ing transcription beyond Pol II pause release.
Considering the Pol II-7SK snRNP interaction studies
and co-occupancy of 7SKwith Pol II at transcribed regions,
Pol II could be envisioned as a platform for 7SK snRNP
recruitment. However, recent findings describing three re-
cruitment mechanisms through factors defined herein as
7SK snRNP chromatin adaptor factors (Ch-AFs) paint an
increasingly exciting and refined picture (Table 2).
First, 5′-terminal half of 7SK binds directly and inde-
pendently of HEXIM1 to the repressive H4R3me2(s) chro-
matin mark at a sub-class of enhancers co-occupied by
Brd4 and jumonji C domain-containing protein JMJD6
(90). This cohort of enhancers, also referred to as anti-
pause enhancers (A-PEs) loop through Mediator to pro-
moters to facilitate P-TEFb-dependent Pol II pause release
at about thousand human genes. Second, 7SK snRNP could
be loaded to promoter-proximal regions containing paused
Pol II by the Kruppel-associated box (KRAB)-interacting
protein KAP1 (91), also referred to as TRIM28 or TIF1,
which has been known mostly for promoting chromatin-
based epigenetic silencing (92). In response to stimulation,
KAP1 functioned as a Ch-AF that continuously tethered
7SK snRNP to promoters of PRGs via binding the ubiq-
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Table 2. Mechanisms directing the anchoring and regulation of canonical 7SK snRNP on chromatin
Anchoring 7SK snRNP to chromatin
Chromatin adaptor factors (Ch-AFs) Factor Mode of action
Repressive chromatin mark H4R3me2(s) Binds first half of 7SK to recruit 7SK snRNP to A-PEs.
Transcription regulator KAP1 (TRIM28 or
TIF1)
Binds LARP7 to recruit 7SK snRNP to promoters.
Non-histone chromatin protein HMGA1 Binds CTIP2 and SL2 of 7SK to recruit 7SK snRNP to promoters.
Releasing P-TEFb from 7SK snRNP
Signal transduction pathways Factor Mode of action
T-cell receptor signaling PKC Phosphorylates HEXIM1 Ser158 to prevent 7SK binding.
ERK ERK-dependent kinase phosphorylates HEXIM1 Tyr271 and Tyr274 to
prevent CycT1/P-TEFb binding.
PI3K/Akt signaling Akt Phosphorylates HEXIM1 Ser270 and Thr278 to prevent CycT1/P-TEFb
binding.
Ca2+-calmodulin-PP2B signaling PP2B + PP1 PP1 dephosphorylates P-Thr186 in Cdk9 after PP2B remodels 7SK
snRNP.
Ca2+-dependent calpain 2 activation Calpain 2 Cleaves MePCE to destabilize core 7SK snRNP.
P-TEFb release factors (P-REFs) Factor Mode of action
HIV-1 transactivator of transcription Tat Binds the distal part in SL1 of 7SK and CycT1 to dislodge HEXIM1;
recruits PPM1G for P-Thr186 Cdk9 dephosphorylation.
HTLV-1 transactivator of
transcription
Tax Binds CycT1 to dislodge HEXIM1.
Inducible transcription factor NF-B Recruits PPM1G for P-Thr186 Cdk9 dephosphorylation.
Splicing and transcription regulator SRSF2 Binds SL3 of 7SK and nascent RNA to trigger the release.
DEAD-box RNA helicase DDX21 Binds SL3 of 7SK and changes conformation of 7SK.
hnRNPs and RNA helicase A hnRNP A1, A2/B1, Q, R
and RNA helicase A
Bind SL3 of 7SK to enable the subsequent release.
Histone demethylase JMJD6 Demethylates H4R3me2(s) and 7SK cap at A-PEs.
Histone acetyltransferase p300 Acetylates CycT1 to dislodge HEXIM1.
Table summarizes principal ways by which 7SK snRNP is anchored to chromatin and by which P-TEFb is released from 7SK snRNP for promoting Pol
II escape from pausing. For each factor, the mode of action is provided. The acronym SL stands for stem loop in 7SK.
uitous 7SK snRNP component LARP7, enabling P-TEFb
recruitment, Pol II elongation and PRGs expression. Judg-
ing from the genome-wide presence of KAP1 with 7SK
snRNP components Cdk9, LARP7 and HEXIM1 in the
vicinity of paused Pol II, the authors estimated that up to
70% of all genes experiencing pausing could be controlled
via the KAP1-7SK snRNP axis. Further work is required
to determine whether KAP1 regulates transcription of so
many genes through 7SK snRNP. Importantly, a preceding
study also identified KAP1 as a regulator of Pol II pausing
(93). Here, phosphorylation of KAP1 at Serine 824 deter-
mined its influence on target gene transcription by Pol II.
While the non-phosphorylated form of KAP1 augmented
Pol II pausing, the phosphorylated KAP1 stimulated Pol
II pause release for productive transcription, suggesting
that this post-translational modification (PTM) might pro-
mote the promoter-proximal phosphorylation actions by
P-TEFb. It remains to be tested, however, whether there
is any connection between KAP1 phosphorylation, 7SK
snRNP tethering and P-TEFb activation. Finally, a spe-
cific subset of 7SK snRNP contains a transcriptional re-
pressor, C2H2-type zing-finger protein CTIP2, which inter-
acts with HEXIM1 and the 7SK SL2 to augment inhibi-
tion of P-TEFb (94). Recruitment of this particular 7SK
snRNP to HIV-1 and specific human gene promoters could
be achieved via the non-histone chromatin proteinHMGA1
that attracts the snRNPby binding CTIP2 and the 7SKSL2
(95).
Taking together, anchoring 7SK snRNP to promoters
and enhancers by Ch-AFs represents an important step
in controlling Pol II pause release by P-TEFb, providing
an opportunity for additional regulatory layers impacting
this critical checkpoint in metazoan gene transcription. In
addition, as global disentanglement of P-TEFb from 7SK
snRNP can be associated with hypertrophic and hyper-
proliferative diseases such as cardiac hypertrophy and can-
cer (96,97), supplying the pre-activated pool of P-TEFb to
paused Pol II at specific genes sets the stage for a controlled
use of P-TEFb by the subsequent transcriptional regulators.
LIBERATING P-TEFb FROM 7SK snRNP
Having realized the critical importance of P-TEFb in
Pol II elongation and that its major pool resides within
7SK snRNP, many investigators have turned their atten-
tion to elucidate mechanisms governing P-TEFb activation
through its release from the inhibitory snRNP (Table 2).
Release of P-TEFb by cellular signal transduction pathways
First, diverse cellular signal transduction pathways con-
verge on almost all 7SK snRNP components to disable
key mechanisms governing the assembly of P-TEFb into
7SK snRNP. As a result, specific PTMs occurring on
Hexim1, Cdk9 and CycT1 as well as MePCE degrada-
tion provoke P-TEFb liberation (Figure 3). In the case of
 at H
elsinki U
niversity Library on N
ovem
ber 6, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
7532 Nucleic Acids Research, 2016, Vol. 44, No. 16
Figure 3. Summary of post-translational modifications and proteolysis of
7SK snRNP components that provoke the release of P-TEFb. The model
represents the canonical 7SK snRNP complex, in which 7SK, LARP7
and MePCE form core 7SK snRNP that enables binding and inhibition
of P-TEFb (Cdk9 is in red) by HEXIM1/2. The arrows depict stimulus-
dependent PTMs of HEXIM1, CycT1 and Cdk9, which lead to the release
of P-TEFb by disabling key steps that promote the assembly of P-TEFb
into 7SK snRNP. Whereas the PTMs in HEXIM1, CycT1 and Cdk9 leave
core 7SK snRNP intact, demethylation of 7SK and proteolysis of MePCE
destabilize the core, yielding irreversible P-TEFb activation.
HEXIM1, its ability to bind 7SK and CycT1 is compro-
mised. Specifically, in response to T-cell receptor (TCR)
signaling, protein kinase C  (PKC) phosphorylated Ser-
ine 158 within the positively-charged 7SK binding region
of HEXIM1, antagonizing HEXIM1-7SK interaction and
thus the subsequent P-TEFb binding and inhibition by
HEXIM1 (98). In addition, phosphorylation of multiple
residues within the unstructured HEXIM1 region just be-
fore the C-terminal coiled-coil CycT1 binding domain in-
terferes with HEXIM1-P-TEFb interaction. Here, hexam-
ethylene bisacetamide (HMBA) treatment triggered phos-
phorylation of Serine 270 and Threonine 278 via PI3K/Akt
pathway (99). Moreover, activating TCR signaling stimu-
lated extracellular-signal-regulated kinase (ERK), leading
to Tyrosine 271 and 274 phosphorylation (100,101). Impor-
tantly, expression of mutant HEXIM1 proteins that could
no longer become phosphorylated at the above residues in-
hibited the global release of P-TEFb from 7SK snRNP and
P-TEFb occupancy at HIV-1 promoter, limiting viral tran-
scription (99,101).
Concerning P-TEFb, its presence and thus inhibition
within 7SK snRNP is controlled directly through dephos-
phorylation and acetylation of Cdk9 and CycT1, respec-
tively. Following UV irradiation or HMBA exposure, a
key role in P-TEFb activation for the calcium (Ca2+)-
calmodulin-protein phosphatase 2B (PP2B) signaling path-
way and protein phosphatase 1 (PP1) was uncovered
(102). Therein, activated by UV or HMBA and facili-
tated by a PP2B-induced conformational change in 7SK
snRNP, PP1 dephosphorylated P-Thr186 in Cdk9, induc-
ing P-TEFb release. Of note, Threonine 186 has to be re-
phosphorylated before P-TEFb could promote Pol II elon-
gation. Finally, histone acetyltransferase p300 acetylated
four Lysine residues within the predicted CycT1 coiled-coil
region, triggering P-TEFb dissociation from HEXIM1 and
thus 7SK snRNP by as of yet undefined mechanism (103).
In the cases of global activation of P-TEFb described
thus far, P-TEFb release from the inhibitory grip by 7SK
snRNP is reversible. This is because the core 7SK snRNP re-
mains intact, serving as a platform that enables subsequent
reassembly of HEXIM1 and P-TEFb. However, P-TEFb
activation could also be irreversible due to destabilization
of core 7SK snRNP. This was demonstrated in the context
of megakaryocyte development, a process characterized by
cellular enlargement and nuclear polyploidization (104).
Early in megakaryopoiesis, high levels of Ca2+ provoked
upregulation and activation of a Ca2+-dependent protease,
calpain 2, which cleaved MePCE directly. Concomitantly,
LARP7 was downregulated in a calpain 2-independent
manner, fully destabilizing 7SK, leading to a global P-TEFb
release and transcriptional upregulation of cytoskeletal reg-
ulatory factors that are essential for megakaryocyte mor-
phogenesis.
Release of P-TEFb by HIV-1 Tat
In addition to cell signaling cascades that result in the
PTMs or proteolysis of 7SK snRNP components, transcrip-
tional regulators defined herein as P-TEFb release factors
(P-REFs) can directly liberate P-TEFb from 7SK snRNP
to stimulate Pol II pause release. This paradigm has been
best illustrated by the way HIV-1 Tat hijacks P-TEFb for
optimal viral transcription. Following initial observations
that HIV-1 infection stimulated global release of P-TEFb
from 7SK snRNP, Tat by itself also released P-TEFb from
7SK snRNP or prevented its sequestration into it in vivo
and in vitro (58,105). Further mechanistic studies have un-
veiled key steps by which HIV-1 Tat and TAR transferred
the repressed P-TEFb to nascent viral transcripts for their
completion. The mechanisms involved are grounded by the
obvious similarity between the HIV-1 TAR-Tat-P-TEFb
and host cell 7SK-HEXIM1-P-TEFb systems. Namely, the
TAR-binding ARM of Tat is very similar to the first half
of 7SK-binding ARM of HEXIM1 (79). Furthermore, the
7SK SL1 carries proximal and distal HEXIM1-binding
segments that are highly similar to the consensus mini-
mal structure of the HIV-1 TAR (78), and both Tat and
HEXIM1 bind CycT1 in a mutually-exclusive manner due
to the shared CycT1 binding site (106,107). While through
its ARM, Tat displaced HEXIM1 from 7SK by interact-
ing with the evolutionarily conserved distal part of the 7SK
SL1 (78), integrity of Tat’s AD was critical for outcompet-
ing HEXIM1 from the CycT1 subunit of P-TEFb, which
stems from about 10-fold higher affinity of Tat for CycT1
(58). Moreover, the Tat-mediated release of P-TEFb from
7SK snRNP was assisted by AFF1 which further increased
the affinity between Tat and P-TEFb (49). Thus, Tat re-
leases P-TEFb through targeting two principal steps that
govern its presence within 7SK snRNP. Of note, the human
T-lymphotropic virus type 1 transcriptional activator Tax
also utilizes P-TEFb for viral transcription and displaces P-
TEFb from 7SK snRNP through binding CycT1 (108,109),
suggesting that P-TEFb liberation from 7SK snRNP could
be a common theme supporting replication of different
viruses in host cells.
Furthermore, at least two additional mechanisms could
play a role in promoting the transfer of P-TEFb by Tat
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from 7SK snRNP to TARat proviral promoter within chro-
matin. As already pointed out, Tat could assemble into
7SK snRNP within the PIC at viral promoter. The local re-
lease of P-TEFb from the snRNP by Tat, however, occurred
only as TAR emerged on the nascent viral transcript from
paused Pol II (86). Thus, the inhibitory 7SK snRNP is re-
leased by competitive binding of the Tat:P–TEFb complex
to TAR as it is transcribed, activating P-TEFb and effec-
tively timing the switch between Pol II pausing and elonga-
tion. Finally, Tat facilitated extraction of P-TEFb from 7SK
snRNP by recruiting the metal-dependent PPM1G/PP2C
phosphatase to HIV-1 promoter, which dephosphorylated
the P-Thr186 in Cdk9 (88). Likewise, Tat might recruit
PP1 to 7SK snRNP to promote P-TEFb release and HIV-
1 transcription. Namely, Tat was reported to interact with
PP1 directly and this PP1 isoform could also dephospho-
rylate the P-Thr186 in Cdk9 (110–112).
Release of P-TEFb by cellular RNA-binding proteins and
transcription regulators
Historically, studying pathogen:host cell interactions has
disclosed vital regulatory mechanisms of host cells, for the
invading microbes usually co-opt them to their own advan-
tage. Following the suit, many cellular regulatory proteins
have been discovered that directly impact 7SK snRNP to
promote P-TEFb activation and subsequent Pol II elonga-
tion.
By analyzing how abrupt Pol II inhibition by DRB and
ActD affected the global pool of 7SK snRNP, investigators
realized that the released P-TEFb and HEXIM1 proteins
were replaced by a series of RBPs that included heteroge-
neous ribonuclear protein (hnRNP) A1, A2/B1, Q, R and
RNAhelicaseA (113,114). TheRBPswithin this alternative
7SK complex termed herein 7SK-hnRNP snRNP assem-
bled onto core 7SK snRNP by binding SL3 of 7SK (114).
Critically, a combined knockdown of HNRNPA1 and HN-
RNPA2 or deletion of the 7SK SL3 precluded the release of
P-TEFb and HEXIM1 in cells with inhibited transcription,
indicating that the binding of the newly identified RBPs
with 7SK is a pre-requisite for P-TEFb activation (113,114).
Because the hnRNPs assemble with the freshly made tran-
scripts and their free pool increases while Pol II is inhibited,
these studies are consistent with amodel in which the global
steady-state pool of P-TEFb released from7SK snRNP cor-
responds to the overall transcriptional demand of the cell.
Importantly, a series of fresh studies have shined a spot-
light on how P-REFs, including individual RBPs and tran-
scription regulators, could impact 7SK snRNP anchored
to promoters and enhancers to provoke P-TEFb activation
and Pol II elongation at specific sets of genes.
First, SRSF2 (formerly known as SC35), amember of the
SR family of proteins which are normally involved in multi-
ple RNAmetabolism steps including constitutive and regu-
lated splicing, was discovered to promote Pol II elongation
at about thousand murine genes in a way that is reminis-
cent to the HIV-1 Tat/TAR system (29). SRSF2 was found
to preferentially occupy active gene promoters, and its de-
pletion decreased global levels of Pol II P-Ser2, causing a
defect in Pol II pause release. Intriguingly, SRSF2 inter-
acted directly with 7SK in living cells, which in turn pro-
moted the binding between SRSF2 and Pol II as well as
promoter occupancy of SRSF2 at its several target genes.
Moreover, SRSF2 bound the 7SK SL3 and was assem-
bled into the canonical 7SK snRNP, in effect mirroring
the Tat-7SK snRNP-Pol II assembly at promoters. In con-
trast to the earlier observation in human cells, about 50% of
7SK snRNP was found to be associated with the chromatin
fraction. Critically, the addition of RNA with high-affinity
binding site for SRSF2 triggered the release of SRSF2 to-
gether with P-TEFb from 7SK snRNP in vitro, and further
in vivo evidence suggested that single-stranded SRSF2 bind-
ing sites on nascent transcripts near TSSs promoted Pol
II pause release through SRSF2. Thus, similar to HIV-1
transcription, it appears that emergence of RNA binding
site from Pol II transcript serves as a switch that liberates
SRSF2 and P-TEFb from 7SK snRNP, triggering produc-
tive Pol II elongation.
In addition to the SR protein SRSF2, the promoter-
bound DEAD-box RNA helicase DDX21 is another mem-
ber of P-REFs that could stimulate Pol II transcrip-
tion through 7SK snRNP (115). By occupying the Pol I-
transcribed rDNA locus in the nucleolus and more than
three thousand active gene promoters with enriched lev-
els of Pol II, DDX21 coordinates multiple steps of ribo-
some biogenesis in human cells. To control specifically Pol
II genes, DDX21 bound 7SK mostly just before and within
SL3 and, as a regulatory component of 7SK snRNP, was
recruited to the promoters of genes encoding ribosomal
proteins and snoRNAs through 7SK. Importantly, DDX21
promoted gene expression in a helicase-dependent manner,
and through its active helicase domain, it induced the re-
lease of P-TEFb from 7SK snRNP in vitro. Hence, this work
suggested that by directly impacting the conformation of
7SK within the snRNP, DDX21 provoked P-TEFb activa-
tion and Pol II pause release at target genes.
While SRSF2 and DDX21 stimulated P-TEFb activa-
tion on chromatin without impacting the stability of 7SK
snRNP, P-TEFb release from the chromatin-anchored 7SK
snRNP at Brd4-JMJD6 co-bound A-PEs is dramatically
different (Figure 4). There, the demethylase activity of
JMJD6 targeted two key steps that otherwise promoted the
anchoring of 7SK snRNP and inhibition of P-TEFb at A-
PEs (90). First, JMJD6 demethylated H4R3me2(s), erasing
the repressive chromatin mark bound directly by 7SK. Sec-
ond, via its demethylase activity, JMJD6 de-capped 7SK by
removing the methyl group from the  -phosphate of the
first 5′ nucleotide of 7SK. Thus, the dual demethylase ac-
tivity of JMJD6 prohibited the anchoring of 7SK snRNP
at A-PEs and destabilized 7SK, releasing P-TEFb that led
to increased Pol II P-Ser2 levels. Correspondingly, knock-
down of JMJD6 as well as BRD4, of which product recruits
JMJD6 toA-PEs, led to increased 7SK andHEXIM1 occu-
pancy at A-PEs, preventing the release of Pol II from paus-
ing at target genes. Illustrating further the role of the re-
pressive chromatin mark in the dynamics of Pol II pause
release at the enhancers, knockdown of PRMT5, which en-
codes the H4R3me2(s) methyltransferase, stimulated Pol II
elongation. Importantly, once released from A-PEs, Brd4
and JMJD6 used their respective P-TEFb interacting do-
mains (PIDs) (90,116) to capture active P-TEFb at target
promoters for Pol II pause release. Besides promoting the
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Figure 4. Brd4 and the dual enzymatic activities of JMJD6 target 7SK
snRNP at anti-pause enhancers to trigger Pol II pause release. A-PEs
(green) contain either tetra-acetylated histone H4 (Lys5, 8, 12 and 16) or
di-acetylated histone H3 (Lys9 and Lys14) (H4/H3Ac), as well as symmet-
ric di-methylated histone H4 (Arg3) (H4R3me2(s)). While the H4/H3Ac
mark recruits JMJD6 via Brd4, the H4R3me2(s) mark is bound directly by
the 7SK SL1 to tether 7SK snRNP harboring inactive P-TEFb (Cdk9 is
in red). The A-PEs loop to target gene promoters through Mediator (not
shown) and stimulate Pol II pause release via a series of events. Through
its histone demethylase activity targeting H4R3me2(s) and RNA demethy-
lase activity targeting the 5′ 7SK methyl-group in its cap structure (Step
1), JMJD6 ablates the anchoring of 7SK snRNP at A-PEs and destabilizes
7SK, respectively. These actions disintegrate 7SK snRNP and release ac-
tive P-TEFb (Cdk9 is in green), which is captured cooperatively by Brd4
and JMJD6 at target gene promoters containing the activeH4/H3Ac chro-
matinmark (Step 2). Finally, P-TEFbphosphorylates its threemain targets
in paused Pol II complex (Step 3), stimulating Pol II elongation.
capturing, Brd4 might employ its PID to further enhance
the kinase activity of P-TEFb (117).
Finally, like Tat at HIV-1 promoter, the activated
NF-B could release P-TEFb from KAP1-tethered 7SK
snRNP at PRGs through recruiting the metal-dependent
PPM1G/PP2C phosphatase, which dephosphorylated the
P-Thr186 in Cdk9 (88,118). Furthermore, upon P-TEFb
release at NF-B-dependent DNA damage-induced genes,
PPM1G bound 7SK and HEXIM1, effectively blocking re-
assembly of P-TEFb into 7SK snRNP to sustain productive
Pol II elongation for duration of the stimulus (118).
ROLES OF 7SK snRNP BEYOND POL II PAUSE RE-
LEASE
Although the role of 7SK snRNP in controlling the es-
cape of Pol II from pausing through P-TEFb has received
tremendous attention and is arguably the dominant func-
tion of the snRNP, it is becoming increasingly clear that
7SK or other components of the canonical 7SK snRNP im-
pact additional steps in Pol II transcription and gene expres-
sion.As already pointed out, 7SKoccupancy resembles that
of Pol II along protein-coding genes (89), raising the possi-
bility that 7SK could affect processes occurring after Pol II
pause release. Indeed, by destabilizing core 7SK snRNP, the
active P-TEFb could stimulate pre-mRNAalternative splic-
ing by augmenting recruitment of SRSF1 (formerly known
as SF2/ASF) and general splicing machinery via increased
Pol II P-Ser2 levels (27). In addition, 7SK depletion led
to failed Pol II termination at thousands of genes in mES
cells (119). Although recent evidence described contribu-
tions of P-TEFb in controlling Pol II termination around
TESs (17,26), more work needs to be done to reveal how
exactly does 7SK prevent read-through transcription.
The recent 7SK ChIRP-seq study revealed a novel role
for 7SK in guarding genomic stability and Pol II initia-
tion (89). Namely, the loss of 7SK provoked an increase of
convergent transcription at promoters, enhancers and par-
ticularly at SEs, which could lead to previously described
AID-initiated genomic instability (120). Indeed, augmented
DNA-damage signaling was observed at the sites. Impor-
tantly, 7SK at enhancers and SEs restricted not only elon-
gation but also initiation by Pol II, clearly distinguishing
these transcribed loci frompromoters where 7SK controlled
Pol II pause release. The authors ascribed the new func-
tion of 7SK at enhancers to its interaction with the mam-
malian ATP-dependent nucleosome-remodeling BAF com-
plex. The canonical 7SK snRNP and the 7SK–BAF snRNP
were found to be mutually exclusive, and by and large they
resided at promoters and enhancers, respectively. Although
only a minor fraction of cellular 7SK was found to be asso-
ciated with BAF components, the high cellular abundance
of 7SK could still translate into about 10 000 7SK–BAF
snRNPs per cell, potentially impacting thousands of en-
hancers across the genome. Curiously, LARP7 andMePCE
failed to co-purify with BAF, suggesting that 7SK bound to
BAF may be stabilized through alternative means. Surpris-
ingly, JQ1, a small molecule bromodomain inhibitor which
is highly specific for dislodging Brd4 from chromatin (121),
interfered with targeting 7SK to enhancers genome wide.
Because previous body of work has never linked Brd4 to any
7SK complexes, future experiments are needed to examine
if Brd4 plays a direct role in promoting the 7SK enhancer
occupancy. Functionally, depletion of 7SK caused stronger
central nucleosome positioning at enhancers and 7SK was
found to be important for scaffolding of BAF with Pol II as
well as for global BAF recruitment to enhancers, suggest-
ing that 7SK facilitates action of BAF, a known inhibitor
of enhancer RNA transcription (122).
Finally, mounting evidence indicates that genes encod-
ing the canonical 7SK snRNP components LARP7 and
HEXIM1 are tumor suppressors. Whereas LARP7 down-
regulation in breast cancer has been proposed to promote
tumorigenesis by transcriptional activation of key regula-
tors stimulating epithelial–mesenchymal transition (96), a
recent study on ubiquitousHEXIM1 silencing inmelanoma
has revealed a dual role of HEXIM1 in suppressing gen-
esis of this cancer (123). While increased HEXIM1 levels
did lead to a defect in paused Pol II release at tumorigenic
genes through decreased 7SK snRNP promoter anchor-
ing, HEXIM1 outside of the 7SK snRNP bound to many
mRNAs including anti-tumorigenic transcripts. The bind-
ing increased stability of examined transcripts, highlight-
ing how under certain circumstances HEXIM1 not only in-
hibits transcription but also promotes gene expression in a
post-transcriptional manner.
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Figure 5. A model of P-TEFb activation on chromatin by 7SK snRNP chromatin adaptor and P-TEFb release factors. The model depicts the P-TEFb
activation and de-activation cycle at gene promoter. Specific 7SK snRNP chromatin adaptor factors (Ch-AFs), i.e. a regulatory protein or a chromatin
mark, direct the anchoring of a fraction of nucleoplasmic 7SK snRNP to chromatin, harboring inactive P-TEFb (Cdk9 is in red) (Step 1). Upon diverse
circumstances, such as cell signaling or emergent nascent transcript, P-TEFb release factors (P-REFs) converge on 7SK snRNP to trigger the liberation of
active P-TEFb (Cdk9 is in green) (Step 2). Subsequently, P-TEFb is assembled into SEC and could in concert with the dedicated transcription factor or P-
REF promote the release of Pol II from pausing (Step 3). Finally, upon the cessation of the signal stimulating gene transcription, P-TEFb is re-sequestered
into 7SK snRNP anchored at promoter (Step 4). Chromatin is represented as a black circle. For clarity, Pol II is omitted from the model. Each of the steps
could be subject to control, and for simplicity, possible regulatory mechanisms are not depicted.
CONCLUSION AND PERSPECTIVES
In keeping with the vital role of P-TEFb in transcription
cycle by Pol II, cells have devised the robust 7SK snRNP
control system to inhibit P-TEFb and enable its delivery in
a pre-activated form to gene promoters for stimulating Pol
II pause release. A view that has emerged from many re-
cent reports is that the canonical 7SK snRNP, once assem-
bled, should not be perceived as an isolated RNP particle
roaming the nucleoplasm, waiting for a signal to eject P-
TEFb. True, a strategy to release P-TEFb globally, includ-
ing from the non-chromatin associated pool of 7SK snRNP,
could be a part of certain gene expression program such as
the one enabling cell proliferation, megakaryopoiesis or re-
covery from UV irradiation-induced DNA damage. Rather
than being inert, 7SK snRNP is contacted by a growing
number of auxiliary factors, which deliver 7SK snRNP to
gene promoters or enhancers and stimulate P-TEFb acti-
vation at appropriate circumstances, respectively, for a con-
trolled gene-specific transition of Pol II from pausing into
productive elongation.
Taking together, we propose a unifying model of P-TEFb
activation on chromatin (Figure 5). In principle, each and
every major step in the model, including the anchoring
of 7SK snRNP to chromatin by Ch-AFs, release of P-
TEFb from 7SK snRNP by P-REFs, assembly of P-TEFb
with transcription factor and SECs, and sequestration of P-
TEFb back into 7SK snRNP upon transcription shutdown,
could be regulated. Hence, many questions remain unan-
swered and interrogating this model warrants intensive fu-
ture experimentation.
For example, are there mechanisms in place that could
stimulate or ablate an interaction between 7SK snRNP and
its chromatin adaptor protein such as KAP1, or an inter-
action between the already assembled 7SK snRNP–KAP1
complex and chromatin? Staying with the theme, how ex-
actly is KAP1 recruited to paused Pol II, and are there
additional Ch-AFs that tether 7SK snRNP to promoters
or enhancers? Intriguingly, TIF1 , a protein of the four
member TIF1 family that includes KAP1, promotes the re-
cruitment of stimulatory Pol II elongation factors including
P-TEFb to erythroid genes (124), suggesting that TIF1
could indeed be another Ch-AF mediating recruitment of
7SK snRNP to chromatin. Likewise, given that P-TEFb re-
lease factors SRSF2 and DDX21 require 7SK for their pro-
moter occupancy, is KAP1 or another Ch-AF involved in
their recruitment?
Another important and little understood issue is how
does P-TEFb, subsequently to its release from 7SK snRNP
on chromatin, become a part of SEC? One attractive possi-
bility is a scenario that might take place in the HIV-1 sys-
tem, whereby Tat releases P-TEFb as a hetero-trimer con-
taining AFF1 (49), which could then serve as a link for
the SEC assembly. Whether AFF1 is globally present at
chromatin-anchored 7SK snRNP and if cellular RBPs and
transcription factors also capture P-TEFb as a trimer re-
mains to be determined. More generally, is chromatin an-
choring of P-TEFb within 7SK snRNP a vital pre-requisite
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for the ability of numerous transcription factors to employ
P-TEFb for stimulating Pol II pause release? Of note, as the
other major pool of P-TEFb (41,42), the Brd4-containing
P-TEFb complex might also serve as a source of P-TEFb
on chromatin. Curiously, the scaffolding SEC components
AFF1 and AFF4 were also detected within the Brd4-P-
TEFb complex (49), indicating that they might direct SEC
assembly upon the possible release of the P-TEFb-AFF1/4
module from Brd4 by transcription factors. Indeed, HIV-1
Tat released P-TEFb from Brd4 (41), suggesting a model in
which SEC could be employed at target cellular genes inde-
pendently of the 7SK snRNP route. Finally, given the siz-
able nucleoplasmic pools of 7SK snRNPandBrd4–P-TEFb
complexes, it remains possible that viral and cellular activa-
tors could also get a handle on P-TEFb off chromatin.
Concerning the 7SK–BAF snRNP, it would be infor-
mative to determine the molecular basis for 7SK-mediated
scaffolding of this novel snRNPwith Pol II, and why is only
a fraction of about 150 000 chromatin-bound BAF com-
plexes associated with 7SK? Finally, is 7SK–BAF snRNP
also subject to such an elaborate regulation as the canonical
7SK snRNP? Given that 7SK–BAF snRNP restricted Pol
II initiation and that 7SK assumes different conformations
within the two 7SK-containing snRNPs (89), it seems likely
that mechanisms other than those impacting the canoni-
cal 7SK snRNP regulate 7SK:BAF interaction. Addressing
these andmany other outstanding challenges, including ob-
taining structures of various 7SK-containing snRNPs, will
undoubtedly move the field to a greater understanding of a
mystery controlled by the string of nucleotides that goes by
the name of 7SK.
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